3-甲基-4-甲基氨基苯酚 | 74789-37-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3-甲基-4-甲基氨基苯酚
• 英文名称: 3-Methyl-4-(methylamino)phenol
• CAS: 74789-37-0
• 化学式: C₈H₁₁NO
• 分子量: 137.18
• InChiKey: BODIKTRHOMTUCO-UHFFFAOYSA-N

物化性质

• 沸点：
  277.7±28.0 °C(Predicted)
• 密度：
  1.109±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

文献信息

• Inhibition Of Phosphoinositide 3-Kinase Beta
  申请人：Jackson Shaun P.

  公开号：US20080319021A1

  公开（公告）日：2008-12-25

  The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.

  本发明涉及选择性磷脂酰肌醇（PI）3-激酶β的抑制剂，使用这些选择性抑制剂进行抗血栓治疗的方法，以及通过检测化合物的PI 3-激酶β的选择性抑制活性筛选有用于新抗血栓治疗的化合物的方法。该发明还涉及新型PI 3-激酶抑制剂化合物。
• Kinase Inhibitors And Methods Of Use Thereof
  申请人：Groneberg Robert

  公开号：US20090023795A1

  公开（公告）日：2009-01-22

  The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.

  式(I)化合物及其药用可接受的盐和前药在治疗和预防由激酶介导的各种疾病中非常有用。
• Therapeutic Morpholino-Substituted Compounds
  申请人：Robertson Alan D.

  公开号：US20080312233A1

  公开（公告）日：2008-12-18

  Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

  Morpholino取代的吡啶并[3,4-d]吡咯啉，喹诺酮和苯并吡喃衍生物抑制磷脂酰肌醇（PI）3-激酶，这是一种调节血小板粘附过程的酶。因此，所述化合物具有抗血栓活性以及其他制药特性。所要求的化合物由公式（I），（II）和（III）表示。PI 3-激酶产生3-磷酸化的PI第二信使，在血流条件下刺激血小板粘附。由于血小板粘附是形成血栓的必要步骤，这些化合物在此类条件下抑制PI 3-激酶抑制或预防血栓形成。这些化合物在治疗PI 3-激酶依赖性疾病方面有用，包括心血管疾病，如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定性心绞痛；呼吸系统疾病，如哮喘，慢性阻塞性肺病（COPD）和支气管炎；炎症性疾病；肿瘤，包括胶质瘤，前列腺癌，小细胞肺癌和乳腺癌等癌症；以及与白细胞功能紊乱相关的疾病，如自身免疫和炎症性疾病。
• Compounds for immunopotentiation
  申请人：Valiante Nicholas

  公开号：US20100226931A1

  公开（公告）日：2010-09-09

  Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed. In a preferred embodiment benzopyrimidine derivatives such as ZD-6474, MLN-518, lapatinib, gefitinib or erlotinib are used.

  本发明公开了刺激免疫反应和治疗对3,4-二（1H-吲哚-3-基）-1H-吡咯-2,5-二酮，链霉菌素类似物，衍生的吡啶并嗪，香豆素-4-酮，吲哚酮，喹唑啉，核苷类似物和其他小分子具有响应性的患者。在一种优选实施方式中，使用苯并嘧啶衍生物，例如ZD-6474，MLN-518，拉帕替尼，吉非替尼或厄洛替尼。
• ANTI-TUMOR AGENT
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1749827A1

  公开（公告）日：2007-02-07

  The present invention provides an antitumor agent and the like, which comprises as an active ingredient, a pyrimidine derivative represented by Formula (I): [wherein -X-Y-Z- represents -O-CR3=N- (wherein R3 represents a hydrogen atom, a substituted or unsubstituted aromatic heterocyclic group and the like) and the like, R1 represents -NR10R11 (wherein R10 and R11 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like) and the like, R2 represents -NR13R14 (wherein R13 and R14 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like)] or a pharmaceutically acceptable salt thereof.

  本发明提供了一种抗肿瘤剂等，其活性成分包括由式（I）表示的嘧啶衍生物： [其中-X-Y-Z-代表-O-CR3=N-（其中 R3 代表氢原子、取代或未取代的芳香杂环基等）等，R1 代表-NR10R11（其中 R10 和 R11 可以相同或不同，各自代表氢原子、R2代表-NR13R14（其中R13和R14可以相同或不同，且各自代表氢原子、取代或未取代的低级烷基等）]或其药学上可接受的盐。